IMNN logo

Imunon Inc. (IMNN)

$0.59

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on IMNN

Market cap

$3853448

EPS

-2.17

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

2.090871

Price on IMNN

Previous close

$0.63

Today's open

$0.61

Day's range

$0.56 - $0.64

52 week range

$0.50 - $4.35

Profile about IMNN

CEO

Stacy R. Lindborg

Employees

20

Headquarters

Lawrenceville, NJ

Exchange

NASDAQ Capital Market

Shares outstanding

6487286

Issue type

Common Stock

IMNN industries and sectors

Healthcare

Biotechnology & Life Sciences

News on IMNN

Imunon, Inc. (IMNN) Q3 2026 Earnings Call Transcript

Imunon, Inc. (IMNN) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 12, 2026

news preview

IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update

IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer

news source

GlobeNewsWire • Nov 12, 2026

news preview

IMUNON Presents New Translational Data at SITC 2026 Demonstrating How IMNN-001 Activates and Sustains Anti-Tumor T-Cell Immunity in Advanced Ovarian Cancer

Analysis of paired patient biopsies from the randomized Phase 2 OVATION 2 study shows IMNN-001 increased CD8+/Treg, CD8+/CD4+ and CD8+/IDO+ ratios in both tumor and stroma

news source

GlobeNewsWire • Nov 6, 2026

news preview

IMUNON to Hold Third Quarter 2026 Financial Results and Business Update Conference Call on Thursday, November 12, 2026

LAWRENCEVILLE, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that the Company will host a conference call at 11:00 a.m.

news source

GlobeNewsWire • Nov 2, 2026

news preview

IMUNON Announces Strategic Sale of ThermoDox®

Agreement with VoxelDox Therapeutics, Inc. Creates a Clear Path to Future Value, Subject to Achievement of Development Milestones in the Planned Phase 1 Glioblastoma Trial

news source

GlobeNewsWire • Oct 21, 2026

news preview

IMUNON to Participate in Upcoming Investor Conferences

LAWRENCEVILLE, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that Stacy Lindborg, Ph.D.

news source

GlobeNewsWire • Oct 8, 2026

news preview

IMUNON Converts $1.2 Million of Debt-to-Equity

Unique investment vehicle provides efficient access to equity capitalOutstanding debt of the original Note lowered by approximately 43% No issuance of common stock or dilutive warrants LAWRENCEVILLE, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), (“IMUNON” or the “Company”), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that it has entered into an Exchange Agreement, under which $1.2 million of outstanding debt, together with accrued and unpaid interest, was exchanged for shares of the Company's newly designated, non-convertible Series B Preferred Stock.

news source

GlobeNewsWire • Sep 29, 2026

news preview

IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan

2026 R&D Day presentation highlights include: Review of final Randomized Phase 2 overall survival results Supportive Preliminary MRD Study Data and translational findings Pathway to confirmatory readout in OVATION 3 Testimonial conversation with an OVATION 1 participant now 10 years from diagnosis LAWRENCEVILLE, N.J., Sept. 24, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today is presenting an update on its IMNN-001 development program for women with newly diagnosed advanced ovarian cancer.

news source

GlobeNewsWire • Sep 24, 2026

news preview

Imunon, Inc. (IMNN) Shareholder/Analyst Call Transcript

Imunon, Inc. (IMNN) Shareholder/Analyst Call Transcript

news source

Seeking Alpha • Sep 23, 2026

news preview

IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review

Independent Data Monitoring Committee recommends the ongoing Phase 2 MRD study continue without modification following its review of all safety data to date

news source

GlobeNewsWire • Sep 22, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Imunon Inc.

Open an M1 investment account to buy and sell Imunon Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in IMNN on M1